At the news
? BULLISHIMPACT 6/10 6-K filed Jun 15, 2026 at 06:10 ET
Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine kinase inhibitor for oncology. The product was a first-to-file and qualifies for 180-day generic exclusivity for this strength. The Bosulif brand had U.S. sales of ~$253.8M over the latest 12 months ended April 2026. This is a positive, event-driven catalyst that expands Dr. Reddy's oncology portfolio, limited to a single strength and a finite exclusivity window.
- First-to-market launch of Bosutinib Tablets 400mg, generic equivalent of Bosulif, in the United States on June 13, 2026.
- Product is a first-to-file, eligible for 180-day generic exclusivity for this strength.
- Brand Bosulif (400mg) had U.S. sales of approximately $253.8 million for the latest 12 months ended April 2026.
- Dr. Reddy's holds exclusive marketing rights; MSN Laboratories is the development and manufacturing partner.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access